Study on the effectiveness of COVID-19 measures in the Netherlands The measures implemented in the Netherlands during the COVID-19 crisis were effective against the spread of the SARS-CoV-2 virus. This is the outcome of a study conducted by RIVM.
PhD research shows: ‘repeating vaccination promotes whooping cough resistance’ Repeating vaccination promotes whooping cough resistance. This is evidenced by the PhD research conducted by Pauline Versteegen. She researched post-vaccination immunity to whooping cough in age groups from 7 to 70 years. On Tuesday 28 May, she was awarded her doctoral degree at Utrecht University.
Continuing significant increase in young adults with gonorrhoea The number of people in the Netherlands with gonorrhoea is continuing to increase significantly. Diagnosed cases of this sexually transmitted infection increased by 31% in 2023, compared to 2022. These cases involved people who were tested at a sexual health centre operated by the Municipal Public Health Services (GGDs).
Air pollution increases risk of infection and severity of illness from COVID-19 People who live in areas with poor air quality are more likely to become infected with SARS-CoV-2. Moreover, the symptoms of COVID-19 are more severe, leading to more hospitalisations and deaths. This is the outcome of a study conducted by RIVM, Utrecht University, Wageningen University & Research and the Netherlands Municipal Public Health Services and Medical Assistance in Accidents and Disasters.
Many serious cases of whooping cough among newborn babies in the Netherlands The number of newborn babies in the Netherlands who are seriously ill due to whooping cough has been increasingly rapidly in recent weeks. About 110 confirmed cases of whooping cough are now being diagnosed every week among children in the Netherlands, including nearly 20 infants.
More than 2.7 million COVID-19 vaccinations administered in the 2023 autumn round In the 2023 autumn round, more than 2,731,000 people in the Netherlands received a COVID-19 vaccination. Vaccination coverage for people over 60 is currently 50.5%. Vaccination coverage varies by age group and region. COVID-19 vaccination was available until 22 December 2023.
Booster vaccinations reduced risk of death from COVID-19 in 2022 Booster vaccinations reduced the risk of dying from COVID-19 in 2022. The risk of death from other causes was also lower for people who had a booster jab than for people without a booster jab. These findings are from research by RIVM.
COVID-19 pandemic made me miss out on a key stage of my life, young people claim Young people aged 12–25 feel that the COVID-19 pandemic made them miss out on a key stage of their lives. They have indicated that important milestones, such as graduation ceremonies or the start of student life, passed them by. This is evident from the latest quarterly study conducted by the Network for Health Research in Disasters.
Vulnerable groups hit hardest by COVID-19 pandemic A new RIVM study has shown that the COVID-19 pandemic intensified existing socio-economic differences. People on lower incomes visited test lanes less often during the pandemic, but were admitted to hospital and intensive care with COVID-19 more often.
Predicting who will experience symptoms after Lyme disease remains challenging Each year, approximately 27,000 people are diagnosed with Lyme disease. For most, the symptoms disappear after treatment with antibiotics. Unfortunately, 25% of those treated have chronic symptoms, such as fatigue, concentration disorders or pain.